As shown in Table 3, the association between prediagnostic lifetime RPA and all-cause mortality following a breast cancer diagnosis was lower among active women (>6.36 h/week of RPA) with breast tumor promoter methylation in APC (HR 0.60, 95% CI 0.40–0.80), CCND2 (HR 0.56, 95% CI 0.32–0.99), HIN (HR 0.55, 95% CI 0.38–0.80), and TWIST1 (HR 0.28, 95% CI 0.14–0.56), but not among active women with unmethylated tumors (p < 0.05 for multiplicative interaction). The gene discussed is APC; the disease is breast cancer.